Compare LPSN & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | CCEL |
|---|---|---|
| Founded | 1995 | 1989 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | EDP Services | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 30.9M |
| IPO Year | 2000 | 2022 |
| Metric | LPSN | CCEL |
|---|---|---|
| Price | $1.95 | $2.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.9K | 3.2K |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $249,838,000.00 | $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $384.00 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.39 | $2.72 |
| 52 Week High | $7.54 | $5.43 |
| Indicator | LPSN | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 42.84 |
| Support Level | $0.39 | $3.02 |
| Resistance Level | $2.44 | $3.92 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 30.14 | 21.51 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.